Novel therapies for high-grade gliomas: A vision for future

Autor: G Kohanbash, C Belka, RE Coleman, D Barba, JH Kim, H Burris, E Razis, C Sturiale, Lesniak, SA Grossman, B Dhokia, MP Gustafson, ZQ Han, P Traxler, AM Sandmair, LM DeAngelis, G Franceschi, P Msaouel, G Kaur, MJ Zhu, S Taillibert, I Yang, M Brown, AT Bruce, HP Kalofonos, T Todo, TC Liu, HS Hochster, KL Black, C Royce, D Fukumura, NL Spector, P Duic, MP Sayers, M Koslow, C Stanton, KL Fink, L Kim, JM Reid, AK Muhammad, JS Yu, AH Friedman, T Gohongi, KA Kreuzer, R Cozens, GP Dunn, DA Haas-Kogan, KB Hymes, JH Sampson, DD Song, RB Herberman, R Ramina, K Kawakami, GG Gomez, N Jelluma, E Galanis, SC Saris, S Thomas, Sy Lim, FM Iwamoto, AJ Grant, H Bender, W Xia, C Wallace, LH Merchant, S Kunwar, RD Schreiber, RE Merchant, AM Kaplan, Vivek Tandon, JS Hardwick, K Ballman, Berger, I Stroud, D Fabbro, JM Piepmeier, WK Yung, JC Hiserodt, K Moore, YB Wang, L Zhang, R Alemany, N Dmitrieva, HJ Choi, KM Kroeger, CD Stiles, D Schiff, LJ Old, JL Clarke, AL Asher, DV Woo, JL Mahaley, R Brandt, P Clement, JI Kreisberg, M Ehtesham, FK Miura, EM Hiesiger, I Cokgor, PY Wen, IK Na, C Crane, LB Nabors, HI Robins, HT Chung, G Ibrahim, NK Kim, A Arista, K Panageas, S Ahmad, RK Jain, KL Penne, JJ Vredenburgh, GD King, M Weller, CT Kuan, T Tihan, H Wakimoto, R Sakalas, CW Reynolds, JC Buckner, S Lassiter, HF Young, M Kioi, H Fukuhara, J Wykosky, MA Vogelbaum, TN Kreisl, H Okada, RE McLendon, V Jendrossek, CJ Wikstrand, P Puranen, M Puranen, W Xiong, Mahaley, YY Kim, C Sauvageot, JA Quinn, SR Husain, S Labropoulos, IF Pollack, CH Tung, J Laterra, JM Dowell, HS Friedman, A Desjardins, EC Dees, K Shah, BK Cho, C Valiengo Lda, GC Gonzalez, P Forsyth, M Assenberg, W Debinski, P Riva, JC Rodrigues, DA Eberhard, S Xia, SM Chang, Jy Yoo, J Hardcastle, CA Kruse, TJ Liu, R Weissleder, Jr MahaleyMS, D Snook, W Roth, Subhashree Mahapatra, M Frattarelli, KC Wang, FF Lang, KA Jaeckle, EA Chiocca, K Terada, C Gomez-Manzano, PR Lowenstein, JJ Kelly, SA Rosenberg, P Selviaridis, Prados, IV Ulasov, E Tyminski, S Sinha, RL Hayes, J Brueggen, T Kuroda, GJ Baker, J Sul, G Simpson, M Rackover, SK Kim, DD Bigner, S Desideri, K Hopkins, XO Breakefield, JN Rich, H Ikeda, M Kawakami, JM Bruner, M Rosenfeld, ND Arvold, PH Aguiar, LW Brady, D Morris, G Roldan, M Candolfi, S Kesari, B Seed, BH Joshi, M Holdhoff, RL Martuza, YG Kwon, SX Jiang, JT Kemshead, M Campone, NL Vujanovic, Y Chen, DA Reardon, TF Cloughesy, A Dispenzieri, M van den Bent, M Kossila, B Hildebrandt, EH Oldfield, S Puri, T Zhang, K Kurozumi, S Loimas, MK Wibowo, C Holder, EM Rosen, H Hurwitz, G Dresemann, EC Kim, H Assi, BL Liu, N Butowski, C Appelt, Groves, EJ Moore, SJ Han, CA Palmer, N Ramakrishna, J Emrich, MJ Maurer, RK Puri, JL Norris, P Waterman, J Clarke, S Piantadosi, T Peery, JF Curtin, LE Abrey, AS Chi, N Courtenay-Luck, A Hemingway, Y Saeki, AB Lassman, V Papanastassiou, J Boni, ED Day, E Hussain, C Miyamoto, AK Mahapatra, R Scholz, AT Parsa, RB Greeno, KL Low, T Mikkelsen, S Chang, C Sarkar, J Fueyo, DV Cramer, PR Allegrini, A Dowlati, DM Gibo, L Xu, M Dey, MM Ames, M Shaffrey, HA McDonald, SB Omay, TR Pawlikowska, RL Hamilton, D George, N Riva, Ashok Kumar Mahapatra, A Immonen, TA Mattei, M Bamberg, X Ye, B Woodhall

Publikováno v: Indian Journal of Neurosurgery, Vol 01, Iss 01, Pp 054-060 (2012)

The treatment for high-grade glioma remains an enigma. The standard treatment using surgery, radiation therapy and chemotherapy for such highly malignant lesions has only yielded modest results, in terms of survival and improving the quality of life

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::831d1b23c52c18a1f1c51646572e45e9
http://www.thieme-connect.de/DOI/DOI?10.4103/2277-9167.94372

Improved Tumor Purity Metrics in Next-generation Sequencing for Clinical Practice: The Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) Approach.

Autor: Patel NM; Department of Pathology and Laboratory Medicine.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Jo H; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Eberhard DA; Department of Pathology and Laboratory Medicine.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Yin X; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Hayward MC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC., Stein MK; Department of Internal Medicine, Division of Hematology and Oncology.; West Cancer Center, University of Tennessee Health Science Center, Memphis, TN., Hayes DN; Department of Internal Medicine, Division of Hematology and Oncology.; West Cancer Center, University of Tennessee Health Science Center, Memphis, TN., Grilley-Olson JE; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.; Department of Internal Medicine, Division of Hematology and Oncology, University of North Carolina School of Medicine.

Publikováno v: Applied immunohistochemistry & molecular morphology : AIMM [Appl Immunohistochem Mol Morphol] 2019 Nov/Dec; Vol. 27 (10), pp. 764-772.

Diagnostic accuracy and prediction increment of markers of epithelial-mesenchymal transition to assess cancer cell detachment from primary tumors.

Autor: Busch EL; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, 3rd Floor, Boston, MA, 02115, USA. nhebu@channing.harvard.edu.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. nhebu@channing.harvard.edu.; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. nhebu@channing.harvard.edu., Don PK; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.; Department of Computer Science and Statistics, University of Rhode Island, Kingston, RI, USA., Chu H; Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, MN, USA., Richardson DB; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA., Keku TO; Department of Medicine, University of North Carolina, Chapel Hill, NC, USA., Eberhard DA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA., Avery CL; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA., Sandler RS; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA.; Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Publikováno v: BMC cancer [BMC Cancer] 2018 Jan 16; Vol. 18 (1), pp. 82. Date of Electronic Publication: 2018 Jan 16.

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.

Autor: Grossman RL; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Abel B; Genomic Health, Redwood City, California, USA., Angiuoli S; Personal Genome Diagnostics, Baltimore, Maryland, USA., Barrett JC; AstraZeneca, Waltham, Massachusetts, USA., Bassett D; Celgene, Seattle, Washington, USA., Bramlett K; Thermo Fisher Scientific, Austin, Texas, USA., Blumenthal GM; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Springs, Maryland, USA., Carlsson A; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA., Cortese R; Seven Bridges, Cambridge, Massachusetts, USA., DiGiovanna J; Seven Bridges, Cambridge, Massachusetts, USA., Davis-Dusenbery B; Seven Bridges, Cambridge, Massachusetts, USA., Dittamore R; Epic Research and Diagnostics, San Diego, California, USA., Eberhard DA; Genomic Health, Redwood City, California, USA., Febbo P; Genomic Health, Redwood City, California, USA., Fitzsimons M; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Flamig Z; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Godsey J; Thermo Fisher Scientific, Waltham, Massachusetts, USA., Goswami J; Thermo Fisher Scientific, Carlsbad, California, USA., Gruen A; Seven Bridges, Cambridge, Massachusetts, USA., Ortuño F; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Han J; Genomic Health, Redwood City, California, USA., Hayes D; University of Michigan, Ann Arbor, Michigan, USA., Hicks J; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA., Holloway D; Seven Bridges, Cambridge, Massachusetts, USA., Hovelson D; University of Michigan, Ann Arbor, Michigan, USA., Johnson J; AstraZeneca, Waltham, Massachusetts, USA., Juhl H; Indivumed GmbH, Hamburg, Germany., Kalamegham R; Genentech, Washington, District of Columbia, USA., Kamal R; Omicia, Oakland, California, USA., Kang Q; University of Michigan, Ann Arbor, Michigan, USA., Kelloff GJ; Office of the Director, National Cancer Institute, Bethesda, Maryland, USA., Klozenbuecher M; Omicia, Oakland, California, USA., Kolatkar A; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA., Kuhn P; Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA., Langone K; Genomic Health, Redwood City, California, USA., Leary R; Novartis Institute for Biomedical Research, Cambridge, Massachusetts, USA., Loverso P; Personal Genome Diagnostics, Baltimore, Maryland, USA., Manmathan H; Seven Bridges, Cambridge, Massachusetts, USA., Martin AM; Novartis Pharmaceuticals, East Hanover, New Jersey, USA., Martini J; Pfizer, San Diego, California, USA., Miller D; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Mitchell M; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Morgan T; University of Michigan, Ann Arbor, Michigan, USA., Mulpuri R; Provista Diagnostics Inc., New York, New York, USA., Nguyen T; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Otto G; Foundation Medicine, Cambridge, Massachusetts, USA., Pathak A; Center for Device and Radiological Health, Food and Drug Administration, Silver Springs, Maryland, USA., Peters E; Genentech, South San Francisco, California, USA., Philip R; Center for Device and Radiological Health, Food and Drug Administration, Silver Springs, Maryland, USA., Posadas E; CytoLumina, Inc., Los Angeles, California, USA.; Cedar-Sinai Medical Center, Los Angeles, California, USA., Reese D; Provista Diagnostics Inc., New York, New York, USA., Reese MG; Omicia, Oakland, California, USA., Robinson D; Novartis Institute for Biomedical Research, Cambridge, Massachusetts, USA., Dei Rossi A; Genomic Health, Redwood City, California, USA., Sakul H; Pfizer, San Diego, California, USA., Schageman J; Thermo Fisher Scientific, Austin, Texas, USA., Singh S; Foundation Medicine, Cambridge, Massachusetts, USA., Scher HI; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Schmitt K; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Silvestro A; Novartis Institute for Biomedical Research, Cambridge, Massachusetts, USA., Simmons J; Personal Genome Diagnostics, Baltimore, Maryland, USA., Simmons T; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Sislow J; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Talasaz A; Guardant Health, Inc., Redwood City, California, USA., Tang P; Center for Data Intensive Science, University of Chicago, Chicago, Illinois, USA., Tewari M; University of Michigan, Ann Arbor, Michigan, USA., Tomlins S; University of Michigan, Ann Arbor, Michigan, USA., Toukhy H; Guardant Health, Inc., Redwood City, California, USA., Tseng HR; CytoLumina, Inc., Los Angeles, California, USA.; Crump Institute for Molecular Imaging, University of California, Los Angeles, California, USA., Tuck M; University of Michigan, Ann Arbor, Michigan, USA., Tzou A; Center for Device and Radiological Health, Food and Drug Administration, Silver Springs, Maryland, USA., Vinson J; Memorial Sloan Kettering Cancer Center, New York, New York, USA., Wang Y; Epic Research and Diagnostics, San Diego, California, USA., Wells W; Open Commons Consortium, Chicago, Illinois, USA., Welsh A; Foundation Medicine, Cambridge, Massachusetts, USA., Wilbanks J; Sage Bionetworks, Seattle, Washington, USA., Wolf J; Provista Diagnostics Inc., New York, New York, USA., Young L; Foundation Medicine, Cambridge, Massachusetts, USA., Lee J; Office of the Director, National Cancer Institute, Bethesda, Maryland, USA., Leiman LC; BloodPAC, Chicago, Illinois, USA.

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2017 May; Vol. 101 (5), pp. 589-592. Date of Electronic Publication: 2017 Apr 12.

Identification of Human Papillomavirus Infection in Cancer Tissue by Targeted Next-generation Sequencing.

Autor: Montgomery ND; Department of Pathology and Laboratory Medicine †Lineberger Comprehensive Cancer Center ‡Department of Medicine, Division of Medical Oncology, The University of North Carolina, Chapel Hill, NC., Parker JS, Eberhard DA, Patel NM, Weck KE, Sharpless NE, Hu Z, Hayes DN, Gulley ML

Publikováno v: Applied immunohistochemistry & molecular morphology : AIMM [Appl Immunohistochem Mol Morphol] 2016 Aug; Vol. 24 (7), pp. 490-5.